Problem dealt with!!!!Fundamentals Behind the Numbers -...

Problem dealt with!!!!

Fundamentals Behind the Numbers - Mesoblast Limited (MSB)

By Bob Kohut | 25.06.2011

Another issue to consider is competition. We have only scratched the surface here, but if you continue your education about the field of regenerative medicine, you will learn the potential is enormous and there are many players in the field.

An industry related search yielded something you will not find on the MSB site. There is another company out there with a competitive patent. Here is a quote we found on stemcelldigest.net:


• Osiris has patents on mesenchymal stem cells (MSCs) obtained from bone marrow. Angioblast has a patent that covers a method of preparing mesenchymal precursor cells by selecting for cells that express the marker STRO-1. Interestingly, this patent apparently does not refer to a source for the MSCs, which raises a question about overlap with the Osiris patent.

The competitor’s name is Osiris, ticker symbol OSIR, and it trades on the US NASDAQ exchange. A direct competitor is not necessarily a reason to stay away from MSB. It simply means Osiris bears close watching.